Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in STRO held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | PERCEPTIVE ADVISORS LLC | 1.3M | $43.3M | +82.4% | 13.484% | 0.65% |
| 2 | BVF INC/IL | 1.3M | $41.6M | 0.0% | 12.935% | 1.06% |
| 3 | Affinity Asset Advisors, LLC | 1.2M | $38.9M | +9.6% | 12.116% | 1.76% |
| 4 | BlackRock, Inc. | 1.1M | $37.3M | +382.5% | 11.601% | 0.00% |
| 5 | Samsara BioCapital, LLC | 1.1M | $35.3M | 0.0% | 10.983% | 2.90% |
| 6 | Kynam Capital Management, LP | 873K | $29.0M | 0.0% | 9.017% | 1.60% |
| 7 | ORBIMED ADVISORS LLC | 744K | $24.7M | -7.1% | 7.688% | 0.46% |
| 8 | BALYASNY ASSET MANAGEMENT L.P. | 711K | $23.6M | +52.7% | 7.349% | 0.03% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 694K | $23.0M | -3.6% | 7.174% | 0.00% |
| 10 | EVENTIDE ASSET MANAGEMENT, LLC | 585K | $19.4M | -18.2% | 6.048% | 0.26% |
| 11 | Velan Capital Investment Management LP | 512K | $17.0M | 0.0% | 5.292% | 10.36% |
| 12 | Woodline Partners LP | 458K | $15.2M | +0.1% | 4.733% | 0.05% |
| 13 | ADAR1 Capital Management, LLC | 404K | $13.4M | -23.0% | 4.175% | 0.61% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 390K | $12.9M | +127.4% | 4.027% | 0.00% |
| 15 | MILLENNIUM MANAGEMENT LLC | 366K | $12.2M | +74.0% | 3.782% | 0.00% |
| 16 | STATE STREET CORP | 306K | $10.2M | +487.1% | 3.162% | 0.00% |
| 17 | Merck & Co., Inc. | 272K | $9.0M | 0.0% | 2.814% | 1.72% |
| 18 | ACUTA CAPITAL PARTNERS, LLC | 270K | $9.0M | +0.3% | 2.793% | 6.25% |
| 19 | AMERIPRISE FINANCIAL INC | 245K | $8.1M | β | 2.528% | 0.00% |
| 20 | Point72 Asset Management, L.P. | 238K | $7.9M | -65.6% | 2.458% | 0.01% |
| 21 | KVP Capital Advisors, LP | 227K | $7.5M | 0.0% | 2.341% | 5.52% |
| 22 | UBS Group AG | 209K | $6.9M | -46.9% | 2.155% | 0.00% |
| 23 | TWO SIGMA INVESTMENTS, LP | 202K | $6.7M | +209.4% | 2.084% | 0.00% |
| 24 | VANGUARD PORTFOLIO MANAGEMENT LLC | 198K | $6.6M | β | 2.042% | 0.00% |
| 25 | MARSHALL WACE, LLP | 175K | $5.8M | -21.3% | 1.811% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in STRO β a direct measure of their conviction.
Filings activity in STRO during Q2 2026, grouped by how each filer changed its position.
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 100 | +27% | 170.53% | +20.80 pp | $533M | +52% |
| Q1 2026 | 79 | +27% | 149.73% | +38.02 pp | $351M | +486% |
| Q4 2025 | 62 | 27% | 111.71% | +11.16 pp | $60M | +38% |
| Q3 2025 | 85 | 16% | 100.55% | 5.59 pp | $43M | +16% |
| Q2 2025 | 101 | 11% | 106.14% | 13.91 pp | $37M | 1.3% |
| Q1 2025 | 114 | 5.0% | 120.05% | +59.09 pp | $38M | 65% |
| Q4 2024 | 120 | 7.0% | 60.96% | +0.60 pp | $109M | 46% |
| Q3 2024 | 129 | β | 60.36% | β | $202M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Institutional ownership and quarterly buying activity across the largest Oncology Biotech peers.
Quick answers to the most common questions about buying STRO stock.
Based on Q2 2026 13F filings, institutional ownership of Sutro Biopharma, Inc. stands at 170.5%, held across 100 reporting institutions.
PERCEPTIVE ADVISORS LLC is the largest reported institutional holder of STRO, with approximately 1,304,846 shares worth $0.04B as of Q2 2026.
Yes β 3 widely-followed marquee investors appear among the top 25 institutional holders of STRO, including MILLENNIUM MANAGEMENT LLC, Point72 Asset Management, L.P., TWO SIGMA INVESTMENTS, LP.
Our composite Smart Money Score for STRO is 77 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
40 institutions opened new positions in STRO during Q2 2026, while 18 fully exited. 52 added to existing positions and 6 trimmed.
STRO institutional ownership rose by 20.80 percentage points quarter-over-quarter, with a net change of +21 holders.
The top 10 institutions account for 59.3% of all reported 13F value in STRO, and the top 25 account for 87.2%.
Across the largest Oncology Biotech peers, institutional ownership levels are: DMRA (200.0%), FTH (54.5%), LONA (184.4%), KYNB (26.9%), CNSY (4.8%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.